Fredrik Schjesvold, MD, PhD, Discusses the Potential of Minimal Residual Disease –Directed Treatment for Multiple Myeloma

Video

CancerNetwork® sat down with Fredrik Schjesvold, MD, PhD, at the 2021 International Myeloma Workshop to talk about minimal residual disease and its importance in the treatment of multiple myeloma.

At the 2021 International Myeloma Workshop, CancerNetwork® spoke with Fredrik Schjesvold, MD, PhD, founder and head of the Oslo Myeloma Center, about the potential of minimal residual disease (MRD)–directed treatment in multiple myeloma.

Transcript:

One of the things that is very actively discussed at this meeting is when, how, and if to move on to MRD-directed treatment, using MRD negativity or positivity to decide whether to move on with treatment or not. That’s being discussed on the basis of fairly little data. We don’t have any data from randomized studies saying whether that’s a good idea or not, we will know the prognostic value of MRD. There are several studies going on both in Europe and the [United States] of randomizing patients to standard or MRD-directed therapy. It’s important that we don’t establish an approach to this before we have data from these studies.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content